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June Supplement 201078S AbstractsObjectives: Cilostazol is known to be a selective inhib-
itor of phosphordiesterase 3 (PDE3) and is generally used
as a pharmacological tool in the patients with peripheral
arterial disease (PAD). Cilostazol has several beneficial
effects, however, little information is available about the
angiogenesis. In the present study, we investigated whether
cilostazol induces improvement of blood flow in the isch-
emic hindlimb of mouse, and if so, examined the mecha-
nisms of angiogenesis.
Methods: Wild-type (WT) mice were separated into
two groups. One is control group that was treated regular
food. The other is cilostazol group that was treated cilosta-
zol as food admixture at a concentration of 0.1%. Ischemic
hindlimb model of mice was made by ligation left femoral
artery and branched artery. Laser Doppler measurements of
blood flowwere compared between the control and cilosta-
zol group, on before and postoperative days 0,3,7 and 14.
The effect of NOS inhibitor (NG-nitro-L-arginine methyl
ester) on cilostazol group was also investigated using Laser
Doppler analysis. Capillary density in histological samples
of adductor muscle immunostained with an anti-CD31
monoclonal antibody was observed on postoperative day
14. The phosphorylation of endothelial nitric oxide syn-
thase (eNOS) was assessed by Western blot analysis on
postoperative day 5.Results: In cilostazol group, an angio-
genesis by laser Doppler measurements of blood flow
(p0.05) and capillary density in adductor muscle
(p0.05) in ischemic hindlimb model of mice were signif-
icantly enhanced compared to non-treated mice (control),
respectively. Cilostazol-induced angiogenesis were signifi-
cantly inhibited by treatment of NOS inhibitor. Western
blot analysis demonstrated that treatment with Cilostazol
induced the increasing in eNOS phosphorylation in isch-
emic tissue.
Conclusions: These results suggest that cilostazol
caused angiogenesis in ischemic hindlimb model of mouse.
This angiogenesis may be due to the enhancement of nitric
oxide production.
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Objectives: Chronic venous insufficiency (CVI) is an
enormous health burden, affecting 2.5 million patients
with advanced disease and leg ulceration per year with costs
in the United States alone exceeding $1 billion annually.
We developed a novel in-vitro cell culture model to exam-ine alterations in the TGF-1 pathway, previously shown to
be disrupted in human venous ulcers.
Methods: Commercially available healthy, adult der-
mal fibroblasts (early passage) were used to represent “nor-
mal fibroblasts” not yet subjected to the pathologic stretch
experienced in CVI. The healthy fibroblasts were incubated
on collagen coated plates, and a Flexercell® strain unit set
to continuous stretch at 21% above ATM with equibiaxial
elongation was used to subject these cells to a pathologic
stretch environment for 1, 5 and 7 days. Alterations in
TGF-1 secretion and TGF-1 Receptor (I and II) expres-
sion in response to mechanical stretch were detected by
fluorescence activated cell sorting analysis (flow cytometry)
and measured by % antibody expression and mean fluores-
cent intensity. Extracellular (secreted) TGF-1 was quan-
tified in media using enzyme linked immunosorbent assay
and fibroblast migratory capacity was measured using the
Boyden chamber transwell migration assay.
Results: TGF-1 secretion from dermal fibroblasts
subjected to 24 hours of stretch was 5-fold less compared to
their control (1169 vs 219 pg/mL, p  0.05). Transwell
migration was also reduced in stretched cells. A significant
reduction in TGF-1 Receptor I expression (70.4% vs
36.1%, p  0.04) following 5 days of mechanical stretch
was also demonstrated.
Conclusions:This model reliably induces reproducible
TGF-1 dysregulation in dermal fibroblasts. Our results
support the observation that pathological dermal stretch is
associated with and plays an integral role in the disruption
of the TGF-1 pathway present in CVI.
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Objectives: The small heat shock protein (HSP27 or
HSPB1) has been implicated in regulating vascular smooth
muscle tone. HSPB1 is phosphorylated by a stress activated
signaling cascade which includes p38 MAP kinase and
MAPKAP kinase II (MK2). The purpose of this investiga-
tion was to determine if HSPB1 expression correlated with
vascular responses in human saphenous vein (HSV).
Methods: Discarded segments of HSV after peripheral/
coronary revascularizations were tested in muscle bath.
Immunoblotting was performed to determine HSPB1
expression.
